This site requires JavaScript to be enabled to work properly. Please modify your settings or use a different browser to continue

      

Leaving GSK Pro

You are leaving GSK Pro to visit a separate website not associated with GSK Pro, a portal for US Healthcare Professionals.There are website links to third-party sites on GSK Pro. GSK is not responsible for content on third-party websites.

Continue

Cancel

THE NUCALA PATIENT

If you have patients like these, NUCALA may help

Patients 6 years and older with severe asthma and:

  • High-dose ICS* plus additional controller
  • 2+ exacerbations in the previous 12 months and/or daily OCS 
  • Baseline blood eosinophils ≥150 cells/μL, which is predictive of efficacy for NUCALA

*For patients 6-11 taking medium- to high-dose ICS + additional controller. See Pediatric Use.

Exacerbations defined as worsening of asthma requiring OCS and/or hospitalization and/or ED visits; for patients ≥12 years on maintenance OCS, exacerbations defined as at least doubling the existing maintenance dose for ≥3 days.

FREQUENT EXACERBATIONS

37-year-old male

FROM AN EXPERT

See how NUCALA can help in this patient type.

 

Medical History and Report

  • Asthma diagnosis at age 28
  • Atopic status: positive (prior SCIT)
  • 3 exacerbations in the past year, 2 requiring hospitalization, no intubations
  • Currently taking high-dose ICS/LABA (9 years) + LAMA (5 years) + LTRA (4 years), nasal corticosteroid spray, albuterol as needed
  • Allergic rhinitis, chronic sinus congestion
  • Persistent dyspnea, intermittent wheezing, symptoms frequently disrupt sleep, frequent use of rescue inhaler
  • Symptoms limit exercise and social activity

Spirometry

  • FEV1: 64% predicted
  • FEV1/FVC ratio: 0.71

Laboratory Assessment

  • CBC with differential
    • Eosinophil count: 428 cells/µL
  •  Total IgE: 140 kU/L

CBC=complete blood count; FEV1=forced expiratory volume in 1 second; FVC=forced vital capacity; ICS=inhaled corticosteroid; IgE=immunoglobulin E; LABA=long-acting beta2-adrenergic agonist; LAMA=long-acting muscarinic antagonist; LTRA=leukotriene receptor antagonist; SCIT=subcutaneous immunotherapy.

FREQUENT EXACERBATIONS AND COMORBID NASAL POLYPS

43-year-old male

FROM AN EXPERT

See how NUCALA can help in this patient type.

 

Medical History and Report

  • Asthma diagnosis at age 18
  • Presence of nasal polyps
  • History of SCIT
  • 2 exacerbations in the past year, including a hospitalization
  • Currently taking high-dose ICS/LABA (13 years) + LTRA (6 years), nasal corticosteroid spray, albuterol as needed
  • Persistent dyspnea, disrupts sleep

Spirometry

  • FEV1: 66% predicted
  • FEV1/FVC ratio: 0.69

Laboratory Assessment

  • CBC with differential
    • Eosinophil count: 324 cells/µL
  • Total IgE: 352 kU/L

OCS DEPENDENT

47-year-old female

FROM AN EXPERT

See how NUCALA can help in this patient type.

 

Medical History and Report

  • Asthma diagnosis at age 29
  • 2 exacerbations in previous 12 months (outpatient, treated with high-dose OCS, 1 hospitalization in the past year)
  • Currently taking OCS 12.5 mg (daily, 9 months), high-dose ICS/LABA (13 years) + LTRA (7 years), albuterol as needed
  • Persistent symptoms have interfered with work and exercise
  • Weight gain of 15 lbs in the last 9 months

Spirometry

  • FEV1: 62% predicted
  • FEV1/FVC ratio: 0.70

Laboratory Assessment

  • CBC with differential
    • Eosinophil count: 157 cells/µL
  • Total IgE: 114 kU/L

PEDIATRIC

10-year-old male

Medical History and Report

  • Asthma diagnosis at age 6
  • 2 exacerbations in the past year; 1 hospitalization in the past year
  • Currently taking high-dose ICS/LABA (3 years) + LAMA (2 years), nasal corticosteroid spray, albuterol as needed
  • Persistent dyspnea, intermittent wheezing, frequent use of rescue inhaler
  • Missed school due to asthma symptoms

Spirometry

  • FEV1: 64% predicted
  • FEV1/FVC ratio: 0.71

Laboratory Assessment

  • CBC with differential
    • Eosinophil count: 370 cells/µL
  • Total IgE: 148 kU/L

ED=emergency department, ICS=inhaled corticosteroids; OCS=oral corticosteroids.